Integrated molecular profiling of juvenile myelomonocytic leukemia

• Published in: Blood 2018-04, Vol.131 (14), p.1576-1586
• Main Authors: Murakami, Norihiro, Okuno, Yusuke, Yoshida, Kenichi, Shiraishi, Yuichi, Nagae, Genta, Suzuki, Kyogo, Narita, Atsushi, Sakaguchi, Hirotoshi, Kawashima, Nozomu, Wang, Xinan, Xu, Yinyan, Chiba, Kenichi, Tanaka, Hiroko, Hama, Asahito, Sanada, Masashi, Ito, Masafumi, Hirayama, Masashi, Watanabe, Arata, Ueno, Toshihide, Kojima, Seiji, Aburatani, Hiroyuki, Mano, Hiroyuki, Miyano, Satoru, Ogawa, Seishi, Takahashi, Yoshiyuki, Muramatsu, Hideki
• Format: Article
• Language: English
• Subjects: Adolescent; Cell Proliferation - drug effects; Cell Proliferation - genetics; Child; Child, Preschool; Crizotinib - pharmacology; DNA Methylation - drug effects; DNA Methylation - genetics; DNA, Neoplasm - genetics; DNA, Neoplasm - metabolism; Female; Gene Expression Profiling; Genome-Wide Association Study; Humans; Infant; Leukemia, Myelomonocytic, Juvenile - drug therapy; Leukemia, Myelomonocytic, Juvenile - genetics; Leukemia, Myelomonocytic, Juvenile - metabolism; Male; Mutation; Oncogene Proteins, Fusion - biosynthesis; Oncogene Proteins, Fusion - genetics; Protein Kinase Inhibitors - pharmacology
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2017-07-798157

Juvenile myelomonocytic leukemia (JMML), a rare and aggressive myelodysplastic/myeloproliferative neoplasm that occurs in infants and during early childhood, is characterized by excessive myelomonocytic cell proliferation. More than 80% of patients harbor germ line and somatic mutations in RAS pathway genes (eg, PTPN11, NF1, NRAS, KRAS, and CBL), and previous studies have identified several biomarkers associated with poor prognosis. However, the molecular pathogenesis of 10% to 20% of patients and the relationships among these biomarkers have not been well defined. To address these issues, we performed an integrated molecular analysis of samples from 150 JMML patients. RNA-sequencing identified ALK/ROS1 tyrosine kinase fusions (DCTN1-ALK, RANBP2-ALK, and TBL1XR1-ROS1) in 3 of 16 patients (18%) who lacked canonical RAS pathway mutations. Crizotinib, an ALK/ROS1 inhibitor, markedly suppressed ALK/ROS1 fusion–positive JMML cell proliferation in vitro. Therefore, we administered crizotinib to a chemotherapy-resistant patient with the RANBP2-ALK fusion who subsequently achieved complete molecular remission. In addition, crizotinib also suppressed proliferation of JMML cells with canonical RAS pathway mutations. Genome-wide methylation analysis identified a hypermethylation profile resembling that of acute myeloid leukemia (AML), which correlated significantly with genetic markers with poor outcomes such as PTPN11/NF1 gene mutations, 2 or more genetic mutations, an AML-type expression profile, and LIN28B expression. In summary, we identified recurrent activated ALK/ROS1 fusions in JMML patients without canonical RAS pathway gene mutations and revealed the relationships among biomarkers for JMML. Crizotinib is a promising candidate drug for the treatment of JMML, particularly in patients with ALK/ROS1 fusions. •Targetable ALK/ROS1 tyrosine kinase fusions were detected in JMML patients without canonical RAS pathway mutations.•Genome-wide methylation analysis identified the hypermethylation profile associated with poor clinical outcome.